JLJared Lamp

Jared Lamp

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jared Lamp has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impaired motor activity in a CRISPR SCA5 L253P knock-in mouse is associated with selective β-III-spectrin subcellular redistribution in the cerebellum

    by Adam W. Avery, Brennon L. O’CAllaghan, Matthew T. Thiel, Sarah A. Denha, Devon G. O’CAllaghan, Emma M. Cismas, Jared Lamp, Harry T. Orr, Thomas S. Hays

    The spinocerebellar ataxia type 5 (SCA5) L253P mutation in β-III-spectrin causes high-affinity actin binding. Here we developed a CRISPR knock-in mouse to determine the i n vivo impact of L253P on Purkinje neurons and motor activity, and to establish a model for future testing of SCA5 therapeutics. Significantly, the knock-in mouse shows impaired motor activity on elevated beam assays at 20 weeks. In the cerebellum, L253P causes a subcellular redistribution of β-III-spectrin in Purkinje neurons. This is marked by loss of β-III-spectrin in distal dendrites, accumulation of β-III-spectrin at the plasma membrane of the soma and proximal dendrites, and formation of inclusions in the soma. The inclusions additionally contain F-actin and α-II-spectrin, accumulate around the nucleus, form at an early age, and are larger in homozygous β-III-spectrin L253P/L253P compared to heterozygous β-III-spectrin L253P/+ mice. In contrast, neurons of the hippocampus and cerebral cortex, where β-III-spectrin is also known to be expressed, abnormally accumulate β-III-spectrin at the plasma membrane but do not form inclusions. To gain greater insight into disease mechanisms, unbiased proteomics identified over 150 cerebellar proteins that physically associate with β-III-spectrin. Of these, cluster analysis revealed a group of 41 proteins, including glutamate receptors, SERCA2, and CaMKII, linked to synaptic transmission. Thus, the effect of the L253P to alter β-III-spectrin localization, including decreased levels in distal dendrites, is likely associated with a disruption of β-III-spectrin function in postsynaptic signaling. Consistent with this, and in agreement with prior findings in knockout mice, the L253P β-III-spectrin knock-in mouse here shows that CaMKII, a calcium sensor and key mediator of glutamate signaling, is ~2-fold activated. Further, the abundance of EAAT4, a glutamate transporter, is significantly reduced. The L253P knock-in mouse primes future preclinical testing of SCA5 therapeutics, such as small molecule modulators of spectrin-actin binding, and glutamate and calcium signaling pathways.

  • Open Access

    Differential SP4 expression and HSP60 abundance in buccal swabs from patients with schizophrenia

    by Christen M. Crosta, Brandon J. Vaglio, Joshua Stuckey, Atul K. Bhattiprolu, Johanne Solis, Jared Lamp, Andrew Umstead, Irving E. Vega, Steven M. Silverstein, Bonnie L. Firestein

    Schizophrenia (SCZ) is heterogenous and polygenic, making it difficult to diagnose and treat. This is expected as diagnostic criteria are solely based on behavioral markers. There is a critical need for easy-to-collect biomarkers that aid in treatment. To identify potential biomarkers, we recruited patients with SCZ and controls. Using buccal cell lysates, we performed real-time quantitative polymerase chain reaction and identified significant differences in Sp4 mRNA between patients and controls. Targeted mass spectrometry identified increased heat shock protein 60 (HSP60) in SCZ samples. To determine the utility of Sp4 mRNA and HSP60 protein as biomarkers, we evaluated their relationship with symptom severity and aberrant cognitive processes. Correlational analyses revealed that elevated Sp4 mRNA and HSP60 protein define a subgroup of patients with SCZ who demonstrate symptomology and poor memory. These data support buccal cell Sp4 mRNA and HSP60 protein as easy-to-collect, candidate SCZ biomarkers for a subset of patients.

  • Open Access

    Cypin regulates K63-linked polyubiquitination to shape synaptic content

    by Srinivasa R. Gandu, Ana R. Rodriguez, Jared Lamp, Mihir V. Patel, Kiran Madura, Irving E. Vega, Bonnie L. Firestein

    An open question in neuroscience is how protein posttranslational modifications regulate synaptic site targeting. Polyubiquitination plays a role in proteasome-mediated protein turnover; however, additional functions for specific types of polyubiquitin linkages have been identified. One type of polyubiquitination, K63-polyubiquitin (K63-polyUb), has been studied for its role in signal transduction within the context of cancer, but little has been done to uncover its role regarding neuronal and synaptic function. Here, we report an emerging function for the cytosolic PSD-95 interactor, cypin, in the regulation of synaptic content by K63-polyUb during neuronal development in vitro and in adult mice in vivo. We identify cypin-promoted K63-polyUb on postsynaptic proteins and also find an important role for cypin in presynaptic function. Our work demonstrates that cypin-promoted changes to K63-polyUb can regulate synaptic content and function on both sides of the synapse, adding important insight into basic mechanisms of neuronal signaling.


  • Open Access

    Polyamination with spermidine enhances pathogenic tau conformations while reducing filamentous aggregate formation in vitro

    by Mohammed M. Alhadidy, Rebecca L. Mueller, Jared Lamp, Nicholas M. Kanaan

    Tau is subject to a broad range of post-translational modifications (PTMs) that regulate its biological activity in health and disease, including microtubule (MT) dynamics, aggregation, and adoption of pathogenic conformations. The most studied PTMs of tau are phosphorylation and acetylation; however, the salience of other PTMs is not fully explored. Tissue transglutaminase (TG) is an enzyme whose activity is elevated in Alzheimer’s disease (AD). TG action on tau may lead to intramolecular and intermolecular cross-linking along with the incorporation of cationic polyamines (e.g., spermidine [SPD]) onto glutamine residues (Q). Even though SPD levels are significantly elevated in AD, the effects of SPD polyamination on tau biology have yet to be examined. In this work, we describe a method to produce recombinant SPD-modified tau where SPD modifications are mainly localized to Q residues within the N-terminus. MT binding and polymerization assays showed that SPD modification does not significantly alter tau’s binding to MTs but increases MT polymerization kinetics. In addition, biochemical and biophysical assays showed that SPD polyamination of tau markedly reduces tau polymerization into filamentous and β-sheet-containing aggregates. On the other hand, SPD modification promotes the formation of pathogenic conformations (e.g., oligomerization and misfolding) by tau with or without inducing tau polymerization. Taken together, these data suggest that SPD polyamination of tau enhances its ability to polymerize MTs and favors the adoption of pathogenic tau conformations but not filamentous aggregates in vitro.


  • Open Access

    Structure and Enzymatic Activity of an Intellectual Disability-Associated Ornithine Decarboxylase Variant, G84R

    by X. Edward Zhou, Chad R. Schultz, Kelly Suino Powell, Amy Henrickson, Jared Lamp, Joseph S. Brunzelle, Borries Demeler, Irving E. Vega, André S. Bachmann, Karsten Melcher

    Ornithine decarboxylase (ODC) is a rate-limiting enzyme for the synthesis of polyamines (PAs). PAs are required for proliferation, and increased ODC activity is associated with cancer and neural over-proliferation. ODC levels and activity are therefore tightly regulated, including through the ODC-specific inhibitor, antizyme AZ1. Recently, ODC G84R has been reported as a partial loss-of-function variant that is associated with intellectual disability and seizures. However, G84 is distant from both the catalytic center and the ODC homodimerization interface. To understand how G84R modulates ODC activity, we have determined the crystal structure of ODC G84R in both the presence and the absence of the cofactor pyridoxal 5-phosphate. The structures show that the replacement of G84 by arginine leads to hydrogen bond formation of R84 with F420, the last residue of the ODC C-terminal helix, a structural element that is involved in the AZ1-mediated proteasomal degradation of ODC. In contrast, the catalytic center is essentially indistinguishable from that of wildtype ODC. We therefore reanalyzed the catalytic activity of ODC G84R and found that it is rescued when the protein is purified in the presence of a reducing agent to mimic the reducing environment of the cytoplasm. This suggests that R84 may exert its neurological effects not through reducing ODC catalytic activity but through misregulation of its AZ1-mediated proteasomal degradation.


  • Open Access

    Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein

    by Joseph R. Patterson, Warren D. Hirst, Jacob W. Howe, Christopher P. Russell, Allyson Cole-Strauss, Christopher J. Kemp, Megan F. Duffy, Jared Lamp, Andrew Umstead, Michael Kubik, et al.

    β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson’s disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca)and protein (α-syn). Effects of β2AR agonist clenbuterol on the levels ofSncamRNA and α-syn protein were evaluated in vivo (rats and mice) and in rat primary cortical neurons by two independent laboratories. A modest decrease inSncamRNA in the substantia nigra was observed after a single acute dose of clenbuterol in rats, however, this decrease was not maintained after multiple doses. In contrast, α-syn protein levels remained unchanged in both single and multiple dosing paradigms. Furthermore, clenbuterol did not decreaseSncain cultured rat primary cortical neurons, or decreaseSncaor α-syn in mice. Additionally, compared to the single-dose paradigm, repeat dosing resulted in substantially lower levels of clenbuterol in plasma and brain tissue in rodents. Based on our observations of a transient decrease inSncaand no effect on α-syn protein in this preclinical study, these data support the conclusion that clenbuterol is not likely a viable disease-modifying strategy for PD.


  • Structure of an AMPK complex in an inactive, ATP-bound state

    by Yan Yan, Somnath Mukherjee, Kaleeckal G. Harikumar, Timothy S. Strutzenberg, X. Edward Zhou, Kelly Suino-Powell, Ting-Hai Xu, Ryan D. Sheldon, Jared Lamp, Joseph S. Brunzelle, et al.

    How to catch a dynamic state: AMP-activated protein kinase (AMPK) is a key sensor of energy status in eukaryotes. Its dynamic structure is regulated by allosteric factors including phosphorylation and binding of nucleotides and metabolites. Yan et al. developed conformation-specific antibodies that trap AMPK in a fully inactive state that has experienced a large, domain-level rotation. Biophysical experiments in cells and in vitro are consistent with the structural work and support a model in which the activation loop is fully exposed in the completely inactive, dephosphorylated state. These structures inform our understanding of the complex allosteric behavior in this crucial metabolic regulator. Science , abe7565, this issue p. 413


  • Open Access

    Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson’s Disease

    by Peipei Li, Bryan A. Killinger, Elizabeth Ensink, Ian Beddows, Ali Yilmaz, Noah Lubben, Jared Lamp, Meghan Schilthuis, Irving E. Vega, Randy Woltjer, et al.

    The gut microbiome can impact brain health and is altered in Parkinson’s disease (PD). The vermiform appendix is a lymphoid tissue in the cecum implicated in the storage and regulation of the gut microbiota. We sought to determine whether the appendix microbiome is altered in PD and to analyze the biological consequences of the microbial alterations. We investigated the changes in the functional microbiota in the appendix of PD patients relative to controls (n = 12 PD, 16 C) by metatranscriptomic analysis. We found microbial dysbiosis affecting lipid metabolism, including an upregulation of bacteria responsible for secondary bile acid synthesis. We then quantitatively measure changes in bile acid abundance in PD relative to the controls in the appendix (n = 15 PD, 12 C) and ileum (n = 20 PD, 20 C). Bile acid analysis in the PD appendix reveals an increase in hydrophobic and secondary bile acids, deoxycholic acid (DCA) and lithocholic acid (LCA). Further proteomic and transcriptomic analysis in the appendix and ileum corroborated these findings, highlighting changes in the PD gut that are consistent with a disruption in bile acid control, including alterations in mediators of cholesterol homeostasis and lipid metabolism. Microbially derived toxic bile acids are heightened in PD, which suggests biliary abnormalities may play a role in PD pathogenesis.


  • Open Access

    Gut microbiome dysbiosis is associated with elevated toxic bile acids in Parkinson’s disease

    by Peipei Li, Bryan A. Killinger, Ian Beddows, Elizabeth Ensink, Ali Yilmaz, Noah Lubben, Jared Lamp, Meghan Schilthuis, Irving E. Vega, Markus Britschgi, et al.

    The gut microbiome can impact brain health and is altered in Parkinson’s disease (PD) patients. Here, we investigate changes in the functional microbiome in the appendix of PD patients relative to controls by metatranscriptomic analysis. We find microbial dysbiosis affecting lipid metabolism, particularly an upregulation of bacteria responsible for secondary bile acid synthesis. Proteomic and transcript analysis corroborates a disruption in cholesterol homeostasis and lipid catabolism. Bile acid analysis reveals an increase in microbially-derived, toxic secondary bile acids. Synucleinopathy in mice induces similar microbiome alterations to those of PD patients. The mouse model of synucleinopathy has elevated DCA and LCA. An analysis of blood markers shows evidence of biliary abnormalities early in PD, including elevated alkaline phosphatase and bilirubin. Increased bilirubin levels are also evident before PD diagnosis. In sum, microbially-derived toxic bile acids are heightened in PD and biliary changes may even precede the onset of overt motor symptoms.